These results suggest that BRAF mutations may be suspected in young adult TERTpWT-IDHWT GBM patients, which provides an opportunity to use molecular diagnostic markers and targeted BRAF V600E/MEK blockade, which has shown promise in pre-clinical models of astrocytoma55,56 and in pediatric and adult patients with BRAF-mutant tumors57. The gene discussed is MAP2K7; the disease is glioblastoma.